Department of Defense Breast Cancer Research Program

Defense Health Program

Department of Defense Breast Cancer Research Program

Funding Opportunities for Fiscal Year 2018

 

FY18 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

 

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

 

Applications submitted to the FY18 BCRP must address one or more of the following overarching challenges:

  • Prevent breast cancer (primary prevention)
  • Identify determinants of breast cancer initiation, risk, or susceptibility
  • Distinguish deadly from non-deadly breast cancers
  • Conquer the problems of over diagnosis and overtreatment
  • Identify what drives breast cancer growth; determine how to stop it
  • Identify why some breast cancers become metastatic
  • Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
  • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
  • Eliminate the mortality associated with metastatic breast cancer

 

http://cdmrp.army.mil/funding/bcrp

 

Breakthrough Award Level 1 & 2– Letter of Intent due November 1, 2018

  • Investigators at all academic levels (or equivalent) are eligible to be names as Principal Investigator (PI).
  • Applications from senior postdoctoral fellows who do not meet the eligibility requirements of the Breakthrough Fellowship Award are encouraged underfunding Level 1 and 2.
  • Each investigator may be named on only one Funding Level 1 application and Funding Level 2 application as a PI or Initiating PI.
  • Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
  • Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.
  • Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
  • When submitting the pre-application, it is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
  • There are no limitations on the number of applications for which an investigator may be named as a
  • Partnering PI. However, submission of applications with the same Partnering PI on multiple applications is discouraged unless they are clearly unique, meaningful collaborations addressing distinct research questions.
  • Additional funds are available for applications submitted under the Partnering PI Option.
  • Clinical trials are not allowed.
  • Submission of a Letter of Intent is required prior to full application submission.
  • Funding Level 1:
  • Maximum funding of $375,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years
  • Funding Level 1 – Partnering PI Option:
  • Maximum funding of $600,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years
  • Funding Level 2:
  • Maximum funding of $750,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years
  • Funding Level 2 – Partnering PI Option:
  • Maximum funding of $1M for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years

 

Breakthrough Award Level 3 & 4– Preproposal due September 14, 2018

  • Independent investigators at all academic levels (or equivalent) are eligible to be names as PI.
  • Each investigator may submit one Funding Level 3 pre-application and on Funding Level 4 pre-application as a PI or Initiating PI.
  • Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
  • Potential impact of the research may be near-terms or long-term, but it must be significant and go beyond an incremental advancement.
  • Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
  • When submitting the pre-application it is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
  • Clinical trials are allowed.
  • There are no limitations on the number of applications for which an investigator may be named as a Partnering PI. However, submission of applications with the same Partnering PI on multiple applications is discouraged unless they are clearly unique, meaningful collaborations addressing distinct research questions.
  • Applications must include two or more breast cancer advocates on their research team.
  • Submission of a preproposal is required; application submission is by invitation only.
  • Funding Level 3:
  • Maximum funding of $2.5M in direct costs (plus indirect costs)
  • Maximum period of performance is 4 years
  • Funding Level 3 – Partnering PI Option:
  • Maximum funding of $4M for direct costs (plus indirect costs)
  • Maximum period of performance is 4 years
  • Funding Level 4 and Funding Level 4 – Partnering PI Option:
  • Maximum funding of $10M for direct costs (plus indirect costs)
  • Maximum period of performance is 4 years